Sanofi Offloads Rare Autoimmune Drug to Recordati in Potential …
WEB3 days ago · Sanofi sold Enjaymo, its humanized monoclonal antibody treatment for the rare autoimmune disorder cold agglutinin disease, to Italy’s Recordati in an agreement potentially worth more than $1 billion. Under the terms of the deal, Milan-based Recordati will pay $825 million upfront and will pledge up to $250 million in sales-based milestones.
Sutimlimab in Cold Agglutinin Disease | New England Journal of …
WEBApr 7, 2021 · Cold agglutinin disease is a rare autoimmune hemolytic anemia characterized by hemolysis that is caused by activation of the classic complement pathway. Sutimlimab, a humanized monoclonal...
Cold Agglutinin Disease: New Direction for an Old Disease
WEBApr 28, 2023 · We start the series off with an article from Drs. Surbhi Shah and Ronald Go, who provide a detailed overview of cold agglutinin disease, an uncommon but serious disorder that can be a challenging diagnosis, and the potential treatment options.
Treatment of Cold Agglutinin Disease | ASH Clinical News
WEBSigbjørn Berentsen, MD, PhD, discusses the diagnosis and management of cold agglutinin disease, a rare subtype of autoimmune hemolytic anemia. This material is repurposed from “How I treat cold agglutinin disease,” published in the March 11, 2021, edition of Blood.
How I treat cold agglutinin disease | Blood - American Society of ...
WEBMar 11, 2021 · How I Treat, Immunobiology and Immunotherapy, Red Cells, Iron, and Erythropoiesis. Topics: anemia, bendamustine, b-lymphocytes, cold hemagglutinin disease, complement system proteins, hemolysis, rituximab, adrenal corticosteroids, glucocorticoids, mineralocorticoids.
Press Room - Sanofi US News
WEBJan 25, 2023 · The US Food and Drug Administration (FDA) has approved the expanded indication for Enjaymo ® (sutimlimab-jome), the first and only treatment of hemolysis in adults with cold agglutinin disease (CAD), to include patients with or …
FDA approves treatment for adults with rare type of anemia
WEBFeb 4, 2022 · The disease is called “cold” agglutinin disease because the red cell destruction occurs at cold temperatures. Patients with CAD have a range in severity of anemia symptoms, which include fatigue,...
Press Room - Sanofi US News
WEBFeb 4, 2022 · CAD, a rare autoimmune hemolytic anemia, is caused by antibodies called cold agglutinins binding to the surface of red blood cells, which starts a process that causes the body’s immune system to mistakenly attack healthy red blood cells and cause their rupture (hemolysis).
Sutimlimab for Cold Agglutinin Disease - PMC - National Center …
WEBCold agglutinin disease (CAD) is a rare form of autoimmune hemolytic anemia (AIHA). It makes up 15% to 30% of AIHAs (Sokol et al., 1981).Its prevalence is 5 to 20 cases per million, and incidence is 2 cases per million per year (Moore & Arnall, 2023).Cold agglutinin disease is twice as common in females compared with males.
Updates on the Diagnosis and Management of Cold Autoimmune …
WEBCold agglutinin disease represents a form of immune-mediated hemolytic anemia whereby an IgM protein either monoclonal or polyclonal deposits complement on the surface of the red blood cell.